Author name: egbiomed

Early Warning for Breast Cancer Metastasis: Molecular Clues from Limitations of Traditional Tests and New Possibilities Breast cancer is the most common cancer among women worldwide, accounting for over one-third of new female cancer cases. Despite advances in treatment, around 20% of early-stage patients still experience metastasis. Traditional markers like CA15-3 and CEA lack sensitivity […]

Early Detection of Pancreatic Cancer: Unlocking the Power of ZFP30 and ZNF781 Methylation Markers Gaps and Limitations in Pancreatic Cancer Diagnosis Pancreatic cancer is notoriously difficult to detect early, with most cases diagnosed at an advanced stage. Common tumor markers like CA19-9 and CEA often lack the sensitivity and specificity needed to guide timely treatment decisions. Research Advances In

EG BioMed specializes in developing innovative blood-based cancer diagnostics centered on DNA methylation technology. The company has been awarded multiple patents both in the U.S. and internationally, including recent patents for early detection of pancreatic cancer (US 12,258,636 B2) and breast cancer (US 12,203,140 B2). These advancements are supported by globally recognized quality certifications—CLIA Laboratory

CHICAGO – April 28–29, 2025 – EG BioMed, a biotechnology company specializing in early cancer detection using methylated circulating cell-free DNA, today announced that it will present three scientific abstracts at the upcoming American Association for Cancer Research® (AACR) Annual Meeting 2025. These studies highlight the use of DNA methylation biomarkers for non-invasive cancer detection

In the highly competitive U.S. precision medicine market, partnering with a reliable CLIA-certified laboratory is a key advantage for businesses seeking to rapidly enter the market. EG BioMed’s CLIA-certified laboratory partnership program offers a strategic solution to overcome market bottlenecks and quickly establish a foothold in the U.S. precision medicine sector. (SeeMore) Comprehensive Regulatory Compliance